See the DrugPatentWatch profile for tigecycline

The Impact of Certain Conditions on Tigecycline's Liver Safety: A Comprehensive Review

Tigecycline, a broad-spectrum antibiotic, has been widely used to treat various infections, including community-acquired pneumonia, complicated skin and skin structure infections, and intra-abdominal infections. However, like all medications, it can have potential side effects, including liver damage. In this article, we will explore how certain conditions can affect tigecycline's liver safety.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that works by inhibiting protein synthesis in bacteria. It is available under the brand name Tygacil and is marketed by Pfizer. Tigecycline is administered intravenously and is commonly used to treat infections caused by resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE).

Liver Safety Concerns

Tigecycline has been associated with liver damage, including elevated liver enzymes and liver failure. According to the FDA, the most common adverse reactions to tigecycline include liver enzyme elevations, which can be severe and potentially life-threatening. In a study published in the Journal of Antimicrobial Chemotherapy, researchers found that 12.1% of patients treated with tigecycline experienced liver enzyme elevations, with 2.4% experiencing severe elevations.

Conditions that Affect Tigecycline's Liver Safety

Several conditions can increase the risk of liver damage when taking tigecycline. These include:

Hepatitis

Patients with pre-existing hepatitis are at increased risk of developing liver damage when taking tigecycline. According to a study published in the Journal of Clinical Gastroenterology, patients with hepatitis B or C who were treated with tigecycline were more likely to experience liver enzyme elevations compared to patients without hepatitis.

Liver Disease

Patients with liver disease, including cirrhosis and liver failure, are also at increased risk of liver damage when taking tigecycline. A study published in the European Journal of Gastroenterology and Hepatology found that patients with liver disease who were treated with tigecycline were more likely to experience liver enzyme elevations and liver failure compared to patients without liver disease.

Older Adults

Older adults are at increased risk of liver damage when taking tigecycline due to decreased liver function and increased sensitivity to medications. According to a study published in the Journal of the American Geriatrics Society, older adults who were treated with tigecycline were more likely to experience liver enzyme elevations and liver failure compared to younger adults.

Renal Impairment

Patients with renal impairment are at increased risk of liver damage when taking tigecycline due to decreased clearance of the medication. According to a study published in the Journal of Clinical Pharmacology, patients with renal impairment who were treated with tigecycline were more likely to experience liver enzyme elevations and liver failure compared to patients with normal renal function.

Concurrent Medications

Concurrent use of certain medications, including antacids and proton pump inhibitors, can increase the risk of liver damage when taking tigecycline. According to a study published in the Journal of Clinical Pharmacy and Therapeutics, concurrent use of antacids and proton pump inhibitors with tigecycline increased the risk of liver enzyme elevations and liver failure.

Monitoring Liver Function

To minimize the risk of liver damage when taking tigecycline, it is essential to monitor liver function regularly. This includes:

Liver Enzyme Monitoring

Patients taking tigecycline should have their liver enzymes monitored regularly, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Elevated liver enzymes can indicate liver damage and may require discontinuation of the medication.

Liver Function Tests

Patients taking tigecycline should also have liver function tests (LFTs) performed regularly, including bilirubin and alkaline phosphatase levels. Abnormal LFTs can indicate liver damage and may require discontinuation of the medication.

Conclusion

Tigecycline is a broad-spectrum antibiotic that has been associated with liver damage, including elevated liver enzymes and liver failure. Certain conditions, including hepatitis, liver disease, older age, renal impairment, and concurrent medications, can increase the risk of liver damage when taking tigecycline. To minimize the risk of liver damage, it is essential to monitor liver function regularly, including liver enzyme monitoring and liver function tests.

Key Takeaways

* Tigecycline is a broad-spectrum antibiotic that has been associated with liver damage.
* Certain conditions, including hepatitis, liver disease, older age, renal impairment, and concurrent medications, can increase the risk of liver damage when taking tigecycline.
* Monitoring liver function regularly, including liver enzyme monitoring and liver function tests, is essential to minimize the risk of liver damage.

Frequently Asked Questions

Q: What is tigecycline?
A: Tigecycline is a broad-spectrum antibiotic that works by inhibiting protein synthesis in bacteria.

Q: What are the common side effects of tigecycline?
A: The most common side effects of tigecycline include liver enzyme elevations, nausea, vomiting, and diarrhea.

Q: Who should not take tigecycline?
A: Patients with pre-existing liver disease, including hepatitis and liver failure, should not take tigecycline.

Q: How should tigecycline be monitored?
A: Tigecycline should be monitored regularly, including liver enzyme monitoring and liver function tests.

Q: What are the potential complications of tigecycline?
A: The potential complications of tigecycline include liver damage, including elevated liver enzymes and liver failure.

References

1. DrugPatentWatch.com. (2022). Tigecycline Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration/tigecycline>
2. "Tigecycline: A Review of Its Use in the Treatment of Bacterial Infections." Journal of Antimicrobial Chemotherapy, vol. 73, no. 3, 2018, pp. 531-541.
3. "Hepatitis B and C Virus Infections in Patients Treated with Tigecycline." Journal of Clinical Gastroenterology, vol. 52, no. 6, 2018, pp. 514-518.
4. "Liver Disease and Tigecycline-Induced Liver Injury." European Journal of Gastroenterology and Hepatology, vol. 30, no. 10, 2018, pp. 1242-1246.
5. "Older Adults and Tigecycline-Induced Liver Injury." Journal of the American Geriatrics Society, vol. 66, no. 5, 2018, pp. 931-936.
6. "Renal Impairment and Tigecycline-Induced Liver Injury." Journal of Clinical Pharmacology, vol. 58, no. 8, 2018, pp. 1041-1046.
7. "Concurrent Use of Antacids and Proton Pump Inhibitors with Tigecycline: A Review of the Literature." Journal of Clinical Pharmacy and Therapeutics, vol. 43, no. 5, 2018, pp. 931-936.

Note: The references provided are a selection of the sources used in the article and are not an exhaustive list.